Nahdi Medical Company

FY 2023 EARNINGS CALL

21 March 2024



FY 2023 Financial Highlights

RESILIENT FINANCIAL PERFORMANCE	In SAR (YoY % Change)	FY 2023	Q4 2023
	Revenue	8.71bn (+1.1%)	2.21bn (+3.6%)
	Gross Profit	3.52bn (-0.7%)	865mn (+1.0%)
	Net Profit	893mn(+0.5%)	171mn (+33.2%)
STRONG CASH FLOW GENERATION	Free Cash Flow SAR <mark>984</mark> mn	Capex 4.4% of revenue	ZERO DEBT
SHAREHOLDER VALUE CREATION	ROA 16.6% Dividend SAR 715mn	ROE 36.2% Payout ratio 80%	EPS SAR6.9 DPS SAR5.5

We exist to add beats to our Guests' lives everyday

To be the most loved & trusted health and wellbeing partner for all our Guests

pharmacy chain In KSA with 1,120 stores

100mn+ Guests / yr

140 +cities serving 95% of KSA population

38 years

OF BUILDING TRUST

83% of Revenue Generated by Nuhdeek Guests

13% **Private Label** & direct imports contribution

+lmn Guests served

through our omnihealth ecosystem



- Care
 - Excellence
 - Collaboration

Mission

Values

Vision

To exceed all our Guests' expectations by providing superior personalised lifecare experiences every day, everywhere

served across pharmacies

16%

Online Contribution

from our e-commerce platforms

6

Polyclinics

delivering 106% revenue growth

Nahdi Medical Company | FY 2023 EARNINGS CALL

5

Our passion for people always delivers value to our Guests



Invested in the success of our people



More than **500,000 hours** of training conducted annually



2nd in Saudi Arabia in 2023. Among the top company in Saudi, GCC and Asia for the 6th consecutive time.

Always cultivating Saudi talents

Strong Partnerships






Human Resource Development Fund Social Development

6

>90% of hiring in 2023 consisting of Saudi nationals.

Guest satisfaction continues to validate our long-term strategy



Source: Company disclosure, Nielsen

* By End of 2023

**Methodology used to identify the brand equity of pharmacies and underlying drivers based on brand saliency, brand positioning, future store visit consideration, guest recommendation, store preference and willingness to pay Nahdi Medical Company | FY 2023 EARNINGS CALL

We are Striving for Excellence – Accolades Q4 2023



Nahdi will continue to strengthen its flagship omnichannel offering while investing in higher margin growth areas

Expanding our Omnichannel Footprint and Strengthen Core Retail offering

Brick & Mortar

Store Mix Optimization 2x Revenues from Destination vs. Neighborhood pharmacies

Geographic Diversification

6 KSA regions (avg. 17% contribution/region)

Balanced Portfolio of Assortments 5 Categories (avg. 20% contribution/category)

UAE Expansion 236% YoY revenue growth 15 pharmacies across UAE



Private Label & Direct Imports

Robust Revenue Generation 13% contribution





Online

Growing Revenue Contribution 16% vs 13% in 2022



More Unique Guest transactions +35% 2.3 million (2023) from 1.7 million

More Sessions +26% 182 million

from 145 million

Nahdi's key differentiator is its diversified integrated omnihealth system

Levolve into a leading omnihealth platform



Healthcare Performance

- Revenue Doubled vs last year
- Total Healthcare business reported Breakeven, despite opening new 3 clinics
- Clinic Guests' visits exceeded 1 million guests, doubling from 2022
- Virtual Consultations Doubled to 565K from 276K consultations last year

Prescription (Build & Borrow)


SAR 101mn healthcare revenue generated SAR140mn to pharmacies (factor 1.4x pharmacies' medicine revenue)

Omni Health

Guest spend increased 3x when exposed to full omni health ecosystem

2023

market headwinds gave us pause to make a series of optimizations, particularly in the Front Shop, to ensure Nahdi is positioned sustainably to continue exceeding Guests expectations every day and everywhere.



Mitigation Actions

Outcomes

Front Shop Turnaround

- Invest in pricing to sustain competitiveness vs online and new channels
- Expedite full potential of Nahdi Online and Global
- Continue nurture strategic partnerships with our vendors / partners

Continue Pharma Growth Momentum

- Capitalize from synergy between healthcare and pharmacy
- Expand provider pharmacies
- Strengthen relationship with private insurance companies

Maintain Healthy Financial Position

- Refuel program to drive cost optimization & efficiencies
- Efficient working capital management to maintain strong cash position
- Creating further value by enhancing diversified portfolio to drive key strategic investments



Total revenue +3.6%; Beauty category +3.3% Q4 23 vs. Q4 22



E-commerce

contribution up

16% from 13%



5000 new SKU's & finalized JBP with top partners



Strong Pharma growth of 6.1% in Q4 23 vs. Q4 22



Polyclinics doubled

to 6 in 2023/2 in O4



Insurance business grew +20%








16.6% ROA & 36.2% ROE



Revenue grew steadily through FY 2023




Revenue in Q4 grew 3.6% yearon-year, driven by the Pharma and Beauty categories registering 6.1% and 3.3% increases, respectively

Strong performance of Nahdi's fastgrowing businesses, with Q4 YoY revenue from Healthcare up 106% and from the UAE up 236%.

Investment in sales promotions of Beauty products during H2 led to Q4 growth, paving the way for similar trends in other Front Shop categories.

Resilient gross profit margin



Gross margin held firm at 40.4%, in line with guidance

The investments in Front Shop marketing mix and sales promotions, was partially offset by nonrecurring inventory provision release of SAR 33mn.

Without the one-time provision release, the gross margin for the second semester reached 39%.


Strong EBITDA outcomes



Highly profitable business

Consistently delivering best in class retail EBITDA margin

Attractive net profit profile




Net profit of SAR 893 million, reflecting a 10.2% margin

Margin remained flat in spite of ongoing investments in strategic initiatives including healthcare, e-commerce, and UAE operations.

Savings from established cost efficiency programs and income generated from Islamic time deposits helped fund these initiatives.

Zero debt with strong cash flow from operations and working capital

Capex



Best-in-class ROA/ ROE

Highly profitable business with industry leading ROE and ROA in 2023.

SAR 1,369mn Net Cash generated from operating activities.


Source: Company disclosure

Nahdi Medical Company | FY 2023 EARNINGS CALL

Consistent dividend distribution to shareholders

Dividends Payout %

SAR/Share



Sustainable and consistent Dividends payouts

In line with the company's dividends distribution policy supported by strong financial performance and high liquidity position.

Winning with our Guests



Engage Guests & Partners Drive Efficiencies & Capabilities Invest in Innovation



THANK YOU

Contacts: Investor Relations Department

Email: <u>IR@nahdi.sa</u>

Website: <u>https://investors.nahdi.sa/</u>

P. O. Box 17129 Jeddah 21484, Saudi Arabia



 \bigcirc

